Lucentis Brings New Label Format Into Focus; Highlights List Most Warnings
Executive Summary
Genentech's macular degeneration therapy Lucentis (ranibizumab) is the first product to carry FDA's new physician labeling format
You may also be interested in...
Lucentis Approval For Wet AMD Includes Less Frequent Dosing Option
FDA's June 30 approval of Genentech's Lucentis (ranibizumab) for the treatment of neovascular (wet) age-related macular degeneration includes the possibility for less frequent, quarterly dosing
Lucentis Approval For Wet AMD Includes Less Frequent Dosing Option
FDA's June 30 approval of Genentech's Lucentis (ranibizumab) for the treatment of neovascular (wet) age-related macular degeneration includes the possibility for less frequent, quarterly dosing
Labeling Format Differentiation Minimized By Rule Implementation Timeline
FDA's implementation timeline for the physician labeling rule may mean that advent of the new labeling format will have limited impact on currently available competing products